Brad H. Rovin

A user-friendly tool for cloud-based whole slide image segmentation with examples from renal histopathology

Catherine P. Jayapandian, Brandon G. Ginley, Ellen M. Quardokus, 2022, Communications Medicine.

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.

H. Heerspink, G. Kirsztajn, P. Canetta, 2023, The New England journal of medicine.

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy

Stefan Härtle, Isabelle M. Ayoub, Brad H. Rovin, 2024, Kidney International Reports.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.